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Poster Session II 105and expanded with different dominant responses detected in differ-
ent donors. In conclusion, we have developed a method for the in-
vitro induction and isolation of functional CMV-specific CD81 T
cells from CMV- donors. This may allow the treatment of serious
CMV-related complications in CMV1 patients transplanted with
a CMV- donor.283
THE USE OF SIROLIMUS COMBINED WITH TACROLIMUS AND LOW-
DOSE METHOTREXATE TO PREVENT GRAFT-VERSUS-HOST DISEASE
FOLLOWING UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Nakamura, R.1, Rodriguez, R.1, Palmer, J.2, Nademanee, A.1, Sun, J.1,
Senitzer, D.1, Pullarkat, V.1, Aljitawi, O.1, Zain, J.1, Snyder, D.1,
Parker, P.M.1, Forman, S.J.1. 1City of Hope National Medical Center,
Duarte, CA; 2City of Hope National Medical Center, Duarte, CA.
The use of sirolimus (siro) combined with tacrolimus (tacro) and
low-dose methotrexate (MTX) recently showed a promising result
in preventing acute GVHD after unrelated donor hematopoietic
stem cell transplantation (MUD-HCT) (Antin et al. Blood 2003).
We studied this approach in 77 patients (female 5 30, male 5 47)
who received a MUD-HCT after full-intensity conditioning
(TBI-VP16: 17, TBI-Cy: 10, BuCy: 3, BEAM: 2) or reduced inten-
sity conditioning (FluMel: 45) from April 2005 to March 2007. Pa-
tient age ranged from 19 to 67 (median 46). The cohort consisted of
20 patients with AML, 19 with ALL, 15 with NHL, 8 with MDS, 5
with MPD, 4 with HD, 3 with CML, and 2 with CLL. Twenty-
seven of 77 patients had low-risk disease (1st/2nd CR, CML-CP,
or MDS-RA). Patients received a bone marrow (n5 15) or periph-
eral blood stem cell graft (n5 62). GVHD prophylaxis consisted of
tacro, siro, and MTX 5 mg/m2 for 3–4 days. High-resolution (HR)
molecular HLA typing was performed for class I and II. Forty-two
pairs were in HRmolecular match in all 10 antigens (HLA-A, B, C,
DR, and DQ). Lack of iKIRL was found in 50 pairs.
After a median follow up of 13 months, 50 are alive. The 1-year
probabilities of overall survival (OS), disease-free survival, relapse,
and non-relapse mortality were 60.6% (95%CI: 52.6–67.6),
55.9% (95%CI: 48.8–62.5), 15.0% (95%CI: 8.5–25.7), and 25.4%
(95%CI: 17.9–35.3), respectively. Severe thrombotic microangiop-
athy was observed in two patients and was reversible.
Acute GVHD grade II-IV and III-IV occurred in 46 (60%) and
17 (22%), respectively. Of 46 patients evaluable, 26 (56.5%) devel-
oped chronicGVHD (225extensive, 45limited).Multivariate anal-
ysis for acute GVHD (II-IV) demonstrated a significantly increased
risk with older age ($ median) (HR 1.9[1.0–3.5], p 5 0.05) and
a trend for patients without lack of iKIRL (HR 1.9[0.9–3.8], p 5
0.08). Degree of HLA match, conditioning regimen, disease risk,
gender mismatch, stem cell source, or CMV serostatus had no sig-
nificant impact on acute GVHD. Reduced intensity conditioning
was associated with better OS (76%) compared with full-intensity
conditioning (38%, p5 0.01), which remained significant in multi-
variate analysis (HR: 0.4[0.2–0.8], p 5 0.02).
In summary, our results show the combination of siro, tacro, and
low-dose MTX is associated with an acute GVHD rate comparable
to our historic data afterMUD-HCT, and associated with a promis-
ingOSwhen combinedwithFluMel reduced-intensity conditioning.284
GRAFT REJECTION AS A TYPE I IMMUNE RESPONSE AMENABLE TO
MODULATION BY TYPE II DONOR T CELLS VIA AN ‘‘INFECTIOUS’’ MECH-
ANISM
Mariotti, J., Foley, J., Amarnath, S., Buxhoeveden, N., Ryan, K.,
Costanzo, C.M., Fowler, D.H. NCI/NIH, Bethesda, MD.
We investigated themechanism(s) whereby rapamycin-generated
donor Th2 cells (Th2R cells) prevent graft rejection after allogeneic
bone marrow transplantation (BMT). Analogous to Th1/Th2 cyto-
kine balance in GVHD, we hypothesized that host-versus-graft re-
activity (HVGR) may involve type I cells amenable to inhibition by
type II cells. Fully MHC-disparate BMT was performed: [BALB/
c(H-2 d) into B6(H-2 b)] or [B6-into-BALB/c]; lethal host irradia-
tion (XRT;1050 cGy); and post-XRT add-back of host T cells (0.1 106). Wild-type (WT) or Th1/Tc1 host T cells mediated rejec-
tion (5/5 and 10/10 mice, respectively); in contrast, host Th2/Tc2
cells yielded full donor chimerism (10/10 mice). STAT1 signaling,
which dictates Th1 differentiation, was required for rejection, as
post-XRT add-back of STAT1 knockout (KO) host T cells yielded
full donor engraftment (5/5 mice). HVGR was quantified by cyto-
kine-capture flow cytometry: host T cells were harvested post-
BMT, stimulated with donor APC, and allospecific host T cells
was enumerated. Mice receiving WT or Th1/Tc1 host T cells
had increased post-BMT allospecific CD41 and CD81 T cells se-
creting IFN-g(cohort [C] #3.C#2; p\0.05; C#4.C#2; p\0.05).
In contrast, Th2/Tc2 or STAT1 KO host T cell add-back yielded
nominally increased alloreactive host T cells (C#3 and C#4.C#5,
p\0.02; C#3.C#6, p\0.002). These results suggested that donor
Th2R cells may prevent rejection by reducing host Th1-type differ-
entiation and promoting host Th2-type differentiation rather than
by mediating host T cell clonal deletion. To evaluate this, allospe-
cific 2C TCR transgenic T cells were utilized as host T cell add-
back; BMT was performed 6 donor Th2R cells. Low-dose donor
Th2R cells relative to host 2CTCR transgenic cells (200:1) resulted
in rejection (5/5 mice); 2C cell expansion and alloreactivity were
nominally decreased by this Th2R cell dose. However, high-dose
Th2R cells (1000:1) promoted full donor engraftment (7/10
mice); rejection prevention was associated with reduced expansion
but not total elimination of 2C cells and reduced 2C cell IFN-g al-
lospecificity (C#11\C#10, p5 .008). Furthermore, in this cohort,
cytokine profile of purified post-BMT 2C cells was analyzed: the
cells were skewed towards a Th2 phenotype (reduced IL-2, IFN-
g; increased IL-4, IL-10). Taken together, Th2R cells prevent re-
jection by a mechanism that promotes type II cytokine ‘‘infectious
transplantation tolerance’’ without allospecific clonal deletion.
Role of Th1/Tc1, Th2/Tc2, STAT1 KO in Graft Rejection: Abrogation
of 2C Cell Rejection by Donor Th2R Cell Infusion
Alloreactive AlloreactiveModel #1
B6/BALB/c
(Inocula)Host CD4
Cells (# CD41
IFN-g 1 T cells; 
103/spleen)Host CD8
Cells (# CD81
IFN-g 1 T cells; 
103/spleen)% Donor
CellsCohort1 BM 1.8 ± 1.8 0 ± 0 88 ± 22 Host T 5.1 ± 1.6 3.1 ± 2.2 -3 BM 1 Host T 772 ± 256 653 ± 218 0.8 ± 04 BM 1 Host T1 2129 ± 723 1787 ± 574 0.8 ± 05 BM 1 Host T2 91 ± 31 22.2 ± 6.6 10 ± 2Model #2
BALB/c/B6
(Inocula)1 BM 0.1 ± 0.1 0.5 ± 0.2 54 ± 52 Host T 24 ± 12 7 ± 1 -3 BM 1 Host T 1249 ± 285 3927 ± 555 1.6 ± 0.36 BM 1 Host T
STAT1 KO48 ± 43 68 ± 54 61 ± 6Model #3
BALB/c/B6
(2C TCR Host
Add-back)Absolute # of
2C TCR Host
T cells
(103/spleen)Absolute # of
2C TCR IFN-g
alloreactive
host T cells
(103/spleen)% Donor
Cells7 BM - - 90 ± 28 Host T 307 ± 56 77 ± 18 -9 BM 1 Host T 3656 ± 1189 817 ± 226 0.4 ± 0.110 BM 1 Host T 1 Donor
Th2R (200:1 ratio)884 ± 144 525 ± 140 1.7 ± 0.311 BM 1 Host T 1 Donor
Th2R (1000:1 ratio)152 ± 43 30 ± 17 92.6 ± 1.2285
APPLYING THE HEMATOPOIETIC CELL TRANSPLANTATION-COMOR-
BIDITY INDEX (HCT-CI) IN MYELOABLATIVE MUD TRANSPLANTS PRE-
DICTS NRM AND OS USING A MODIFIED 2-GROUP SCORING SYSTEM
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